<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Omeprazole and sodium bicarbonate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Omeprazole and sodium bicarbonate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Omeprazole and sodium bicarbonate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10322" href="/d/html/10322.html" rel="external">see "Omeprazole and sodium bicarbonate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11511" href="/d/html/11511.html" rel="external">see "Omeprazole and sodium bicarbonate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2874244"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Konvomep;</li>
<li>OmePPi;</li>
<li>Zegerid;</li>
<li>Zegerid OTC [OTC] [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F5932829"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Proton Pump Inhibitor</span>;</li>
<li>
<span class="list-set-name">Substituted Benzimidazole</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812602"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage listed is for omeprazole component; both strengths of Zegerid capsule and powder for oral suspension have identical sodium bicarbonate content. Do not substitute two 20 mg capsules/packets for one 40 mg dose. Recognizing that this formulation has not received FDA approval for use in children despite an approved dosage for omeprazole in children and considering that omeprazole has been used safely in children as an extemporaneous formulation with sodium bicarbonate, the following dosage is recommended:</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce47ce73-fbfd-4c54-81d2-f67675bc530e">Erosive esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i>
<b>Note:</b> Duration of therapy is dependent on age: Infant duration is up to 6 weeks and children and adolescent duration is 4 to 8 weeks. In children and adolescents with no response at 8 weeks, treatment may continue to an additional 4 weeks. For recurrence of erosive esophagitis or gastroesophageal reflux disease (GERD) symptoms (eg, heartburn), an additional 4- to 8-week course may be considered.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">3 to &lt;5 kg: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">5 kg to &lt;10 kg: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">10 kg to &lt;20 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥20 kg: 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance of healing: </i>Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">5 kg to &lt;10 kg: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">10 kg to &lt;20 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥20 kg: 20 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5e4b52c-2ae7-4d5e-bc41-9d176e2d94e2">Gastroesophageal reflux disease, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease (GERD), symptomatic: </b>
<b>Note: </b>Guidelines recommend a 4- to 8-week treatment course; if improvement seen after 4 to 8 weeks, consider possible wean; if no response after 4 to 8 weeks, reevaluate diagnosis and consider referral to pediatric GI specialist (NASPGHAN/ESPGHAN [Rosen 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-based dosing: Infants, Children, and Adolescents: Oral: 0.7 to 4 mg/kg/day (AAP [Lightdale 2013]; NASPGHAN/ESPGHAN [Rosen 2018]); the dose most frequently reported to provide healing of esophagitis and relief of GERD symptoms is 1 mg/kg/day (Zimmerman 2001); maximum daily dose: 40 mg/<b>day</b> (NASPGHAN/ESPGHAN [Rosen 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing: Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">5 kg to &lt;10 kg: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">10 kg to &lt;20 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥20 kg: 20 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Oral: Based on experience in adults, some experts recommend a step-down approach in order to avoid worsening or rebound symptoms. One recommendation is to decrease the dose by 50% over 2 to 4 weeks. If the patient is already on the lowest possible dose, alternate day therapy may be considered. If symptoms worsen during treatment or after discontinuation, patient should be reevaluated (Kim 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729802"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Infants, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe impairment: </b>There are no pediatric-specific recommendations available; based on experience in adult patients, no dosage adjustments are recommended.</p></div>
<div class="block dohp drugH1Div" id="F52729803"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on increased bioavailability, a dosage adjustment should be considered, especially for maintenance of healing of erosive esophagitis. Pediatric-specific recommendations are not available.</p></div>
<div class="block doa drugH1Div" id="F2874285"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10322" href="/d/html/10322.html" rel="external">see "Omeprazole and sodium bicarbonate: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> All doses are based on the omeprazole component.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Avoid coadministration with other antisecretory agents due to decreased acid-inhibitory effects. If another antisecretory agent is needed, allow a sufficient time interval between administration (ie, morning omeprazole and bedtime H<sub>2</sub>RA) (ACG [Katz 2013]; Wolfe 2000; Wolfe 2020).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af13b8bc-31d9-4d53-ade6-d0f129e2f0f1">Gastroesophageal reflux disease, erosive or nonerosive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, erosive or nonerosive:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Mild/intermittent disease (&lt;2 episodes/week) and no evidence of erosive esophagitis: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts reserve proton pump inhibitors (PPIs) for patients who have residual acid reflux symptoms despite twice-daily H<sub>2</sub>RA (Kahrilas 2020).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 10 mg once daily; can increase to 20 mg once daily after 4 to 8 weeks if necessary. Discontinue once asymptomatic for 8 weeks (Festen 1999; Kahrilas 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Severe and/or frequent symptoms (≥2 episodes/week) and/or erosive esophagitis:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 20 to 40 mg once daily; once symptoms are controlled, continue for at least 8 weeks (Kahrilas 2020; Province of British Columbia Ministry of Health 2015; Waghray 2019; Wolfe 2000). Subsequently, patients without erosive esophagitis or Barrett esophagus can taper to the lowest dose necessary to control symptoms (and/or switch to an H<sub>2</sub>RA blocker) then discontinue acid suppression once asymptomatic. Patients with erosive esophagitis or Barrett esophagus should continue long-term maintenance therapy with 20 mg once daily (Kahrilas 2020; Ramakrishnan 2002; Spechler 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Residual symptoms despite 40 mg once daily therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Referral to a specialist is recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Options include splitting the dose to 20 mg twice daily, increasing the dose to 40 mg twice daily, or switching to another PPI (ACG [Katz 2013]; Fass 2020; Wang 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>OTC labeling (patient-guided therapy): </i></b>Heartburn, frequent symptoms (≥2 episodes/week):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 20 mg once daily for 14 days (maximum: 20 mg/day); may repeat a 14-day course every 4 months if needed. Seek medical referral if symptoms do not resolve within 14 days of treatment; do not take for &gt;14 days or more often than every 4 months unless directed by a physician (manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a452940-c4b2-4e83-b889-1684a62dda20">Peptic ulcer disease, treatment and secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease, treatment and secondary prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients on nonsteroidal anti-inflammatory drugs (NSAIDs) (including aspirin), the NSAID should be discontinued, if possible (Feldman 2020). If present, <i>Helicobacter</i>
<i> pylori</i> infection should be treated first; uncomplicated <i>H. pylori–</i>associated ulcers may not need PPI treatment beyond that included in the eradication regimen (Vakil 2020a).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated ulcer: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 20 to 40 mg once daily. Duration depends on the size, location, and cause of the ulcer and ranges from 4 to 8 weeks. In patients with refractory or recurrent disease, may increase the dose to 20 to 40 mg twice daily (Vakil 2020a; Vakil 2020b).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ddad78db-4422-47a9-8299-1c11f40d1828">Stress ulcer prophylaxis in select critically ill patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress ulcer prophylaxis in select critically ill patients: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used in critically ill patients with risk factors for GI bleeding (eg, coagulopathy, mechanical ventilation for &gt;48 hours, traumatic brain injury, history of GI ulceration or bleeding within past year, extensive burns) (SSC [Evans 2021]; Weinhouse 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral or via NG tube (oral suspension or capsule [off label]):</b> 40 mg once daily (ASHP 1999; Levy 1997) <b>or </b>40 mg initially, then another 40 mg dose given 6 to 8 hours later, followed by 40 mg once daily (Conrad 2005; manufacturer’s labeling [Konvomep; Zegerid for oral suspension]). Discontinue prophylaxis once risk factors have resolved (SSC [Evans 2021]; Weinhouse 2022). <b>Note: </b>The capsule dosage form should <b>not</b> be given via NG tube.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy: </b></i>In patients who have received continuous therapy for &gt;6 months, some experts gradually taper therapy until discontinuation to avoid worsening or rebound symptoms. There is no single agreed upon discontinuation strategy. If the patient is receiving 40 mg once or twice daily, some experts decrease the dose by 50% every week. For patients receiving twice-daily dosing, the first dose reduction can be achieved by decreasing to once-daily AM dosing. Once patients are on the lowest dose for 1 week, discontinue therapy (Wolfe 2020). An alternative strategy is to decrease the dose by 50% over 2 to 4 weeks, then discontinue. If the patient is already on the lowest possible dose, alternate-day therapy may be considered (Kim 2018). In addition, as-needed therapy with an H<sub>2</sub>RA or an antacid can be used during the taper (Haastrup 2014).</p></div>
<div class="block dora drugH1Div" id="F50991512"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. </p></div>
<div class="block doha drugH1Div" id="F50988887"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Mild to severe impairment (Child-Pugh class A, B, or C):</b> There are no specific dosage adjustments provided in the manufacturer’s labeling. Exposure is significantly increased in patients with hepatic impairment. The manufacturer’s labeling recommends to avoid use for the maintenance healing of erosive esophagitis.</p></div>
<div class="block adr drugH1Div" id="F2874259"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse events reported from a trial of 178 critically ill adults receiving the oral powder for suspension. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (11%), hypokalemia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hospital-acquired pneumonia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (6%), bradycardia (4%), edema (3%), hypertension (8%), hypotension (10%), supraventricular tachycardia (3%), tachycardia (3%), ventricular tachycardia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Pressure ulcer (3%), skin rash (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (2%), hypernatremia (2%), hypervolemia (5%), hypocalcemia (6%), hypoglycemia (3%), hypomagnesemia (10%), hyponatremia (4%), hypophosphatemia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (5%), decreased gastrointestinal motility (2%), diarrhea (4%), oral candidiasis (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (8%; exacerbation of anemia: 2%), thrombocytopenia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (2%), sepsis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (3%), hyperpyrexia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress (3%), respiratory failure (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Respiratory: Pneumothorax</p></div>
<div class="block coi drugH1Div" id="F2874255"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, urticaria) to omeprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation; concomitant use with products that contain rilpivirine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food; vomiting with blood, or bloody or black stools; heartburn with lightheadedness, sweating, or dizziness; chest pain or shoulder pain with shortness of breath, sweating, pain spreading to arms, neck, or shoulders, or lightheadedness; frequent chest pain.</p></div>
<div class="block war drugH1Div" id="F2874256"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinoma: In long-term (2-year) studies in rats, omeprazole produced a dose-related increase in gastric carcinoid tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to omeprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are needed to rule out the possibility of an increased risk for the development of tumors in humans receiving long-term therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous and systemic lupus erythematosus: Has been reported as new onset or exacerbation of existing autoimmune disease; most cases were cutaneous lupus erythematosus (CLE), most commonly, subacute CLE (occurring within weeks to years after continuous therapy). Systemic lupus erythematosus (SLE) is less common (typically occurs within days to years after initiating treatment) and occurred primarily in young and older adults. Discontinue therapy if signs or symptoms of CLE or SLE occur and refer to specialist for evaluation; most patients improve 4 to 12 weeks after discontinuation of omeprazole.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe cutaneous adverse reactions, including acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fundic gland polyps: Use of proton pump inhibitors (PPIs) increases risk of fundic gland polyps, especially with long-term use &gt;1 year. May occur without symptoms, but nausea, vomiting, or abdominal pain may occur; GI bleeding and/or anemia may occur with ulcerated polyps. Diagnosis of polyps may also increase risk for small intestinal blockage. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Hypomagnesemia may lead to or exacerbate hypocalcemia in patients at risk (eg, hypoparathyroidism). Hypomagnesemia may also lead to hypokalemia. Hypomagnesemia and hypocalcemia may be corrected by magnesium/calcium supplementation, although discontinuation of omeprazole may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tubulointerstitial nephritis: Acute tubulointerstitial nephritis has been observed in patients taking PPIs; may occur at any time during therapy. Patients may present with symptomatic hypersensitivity reaction to nonspecific symptoms of impaired kidney function (eg, anorexia, malaise, nausea); may be diagnosed with biopsy and in the absence of extra-renal manifestations (eg, fever, rash, arthralgia). Discontinue and evaluate patients if acute tubulointerstitial nephritis is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin B<sub>12</sub> deficiency: Prolonged treatment (≥2 years) of PPIs may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acid-base balance disorders: Avoid use in patients with acid-base disorders; contains sodium bicarbonate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bartter's syndrome: Avoid use in patients with Bartter's syndrome; contains sodium bicarbonate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal infection (eg, <i>Salmonella, Campylobacter</i>): Use of PPIs may increase risk of these infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use with caution in patients with heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Exposure is significantly increased in patients with hepatic impairment; avoid use for maintenance healing of erosive esophagitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Avoid use in patients with hypocalcemia; contains sodium bicarbonate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Avoid use in patients with hypokalemia; contains sodium bicarbonate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010; Levine 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asian ethnicity: Exposure increased in patients of Asian descent; avoid use for maintenance of healing of erosive esophagitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Bioavailability may be increased in older adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium-restricted diets: Use with caution in patients on sodium-restricted diets; contains sodium bicarbonate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and kidney and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop omeprazole treatment at least 14 days before CgA test; if initial CgA levels are high, repeat test to confirm. Use same commercial laboratory for testing to prevent variable results.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools. Prior to use, patients should contact healthcare provider if they have heartburn for &gt;3 months, heartburn with dizziness, lightheadedness, or sweating, MI symptoms, frequent chest pain, frequent wheezing (especially with heartburn), unexplained weight loss, nausea/vomiting, stomach pain, on a sodium-restricted diet, or are taking antifungals, HIV antivirals, diazepam, digoxin, tacrolimus, warfarin or other prescription medications. Patients should stop use and consult a healthcare provider if heartburn continues or worsens, or if they need to take for &gt;14 days or more often than every 4 months. Patients should be informed that it may take 1 to 4 days for full effect to be seen.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53406709"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use of gastric acid inhibitors, including proton pump inhibitors (PPIs) and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients 4 to 36 months of age (Canani 2006). Routine use in preterm infants is not recommended (AAP [Eichenwald 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Gastric acid suppression medications have been associated with an increase in <i>Clostridioides</i>
<i>difficile</i> infection (CDI) and recurrent CDI in pediatric patients (Nylund 2014). In a retrospective, observational, case control study of pediatric patients 1 to 18 years old who were hospitalized for diarrhea and abdominal pain, the use of PPIs was significantly higher in patients who tested positive for <i>C. difficile</i> compared to patients who tested negative for <i>C. difficile</i> (22.1% vs 5.9%) (Turco 2010). Consider CDI diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>
<p style="text-indent:0em;margin-top:2em;">A large retrospective cohort study reviewed records for patients with a low baseline risk for fractures who were initiated on acid suppression therapy in the first year of life and evaluated the fracture risk in the first 5 years of life; a total of 97,286 patients were prescribed acid suppression therapy; 73% were prescribed H<sub>2</sub> blockers, 9% were prescribed PPIs, and 18% were prescribed both. H<sub>2</sub> blocker use alone was not associated with an increased fracture hazard; however, PPI use was associated with a 21% increase and use of PPI plus H<sub>2</sub> blocker was associated with a 30% increase. Longer duration of therapy and earlier age at initiation seemed to also increase the fracture hazard. Study findings do not establish a causal relationship between PPI use and fractures. If acid suppression therapy is necessary in the first year of life, limiting therapy to a single drug and limiting the duration should be considered (Malchodi 2019). A second large cohort study reviewed records for 115,933 children &lt;18 years initiated on a PPI. PPI initiation was associated with a statistically significant 11% relative increase in risk of any fracture in patients ≥6 years. The increased risk also seemed to be more pronounced with a longer cumulative duration of PPI use (Wang 2020).</p></div>
<div class="block foc drugH1Div" id="F2874302"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">OmePPi: Omeprazole 20 mg and sodium bicarbonate 1100 mg, Omeprazole 40 mg and sodium bicarbonate 1100 mg [contains sodium 304 mg (13 mEq) per capsule]</p>
<p style="text-indent:-2em;margin-left:4em;">Zegerid: Omeprazole 20 mg and sodium bicarbonate 1100 mg, Omeprazole 40 mg and sodium bicarbonate 1100 mg [contains sodium 304 mg (13 mEq) per capsule]</p>
<p style="text-indent:-2em;margin-left:4em;">Zegerid OTC: Omeprazole 20 mg and sodium bicarbonate 1100 mg [contains sodium 303 mg (13 mEq) per capsule] [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Omeprazole 20 mg and sodium bicarbonate 1100 mg; Omeprazole 40 mg and sodium bicarbonate 1100 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for suspension, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Konvomep: Omeprazole 2 mg and sodium bicarbonate 84 mg per 1 mL (90 mL, 150 mL, 300 mL) [contains fd&amp;c red #40, propylene glycol; strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">Zegerid: Omeprazole 20 mg and sodium bicarbonate 1680 mg per packet (30s) [contains sodium 460 mg (20 mEq) per packet]; Omeprazole 40 mg and sodium bicarbonate 1680 mg per packet (30s) [contains sodium 460 mg (20 mEq) per packet]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Omeprazole 20 mg and sodium bicarbonate 1680 mg per packet (30s); Omeprazole 40 mg and sodium bicarbonate 1680 mg per packet (30s)</p></div>
<div class="block geq drugH1Div" id="F2874245"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422180"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Omeprazole-Sodium Bicarbonate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20-1100 mg (per each): $104.84 - $113.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40-1100 mg (per each): $13.34 - $113.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Zegerid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20-1100 mg (per each): $132.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40-1100 mg (per each): $132.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Omeprazole-Sodium Bicarbonate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20-1680 mg (per each): $104.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40-1680 mg (per each): $104.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Zegerid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20-1680 mg (per each): $132.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40-1680 mg (per each): $132.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Konvomep Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-84 mg/mL (per mL): $2.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block exp drugH1Div" id="F11430489"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">
<b>2 mg/mL Oral Suspension</b></p>
<p style="text-indent:0em;margin-top:2em;">A 2 mg/mL oral suspension may be made with omeprazole-sodium bicarbonate powder and water. Pour the contents of six 20 mg omeprazole-sodium bicarbonate packets into a glass mortar. Add 30 mL water to the powder and mix to a uniform paste; mix while adding water in incremental proportions to <b>almost</b> 60 mL; transfer to a 60 mL bottle, rinse mortar with water, and add sufficient quantity of water to make 60 mL. Label "shake well" and "refrigerate". Stable for 45 days refrigerated.</p>
<div class="reference">Johnson CE, Cober MP, and Ludwig JL, "Stability of Partial Doses of Omeprazole-Sodium Bicarbonate Oral Suspension," <i>Ann Pharmacother</i>, 2007, 41(12):1954-61.<span class="pubmed-id">17956960</span></div>
</div>
<div class="block adip drugH1Div" id="F53569377"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Each capsule of omeprazole-sodium bicarbonate contains 1,100 mg (13 mEq) of sodium bicarbonate; total Na content is 304 mg and 303 mg for the prescription and OTC product, respectively. Each packet of omeprazole-sodium bicarbonate powder for oral suspension contains 1,680 mg (20 mEq) of sodium bicarbonate; total Na content is 460 mg.</p></div>
<div class="block admp drugH1Div" id="F52614163"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Both strengths of capsule and Zegerid powder for oral suspension have identical sodium bicarbonate content. Do not substitute two 20 mg capsules/packets for one 40 mg dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Oral: Should be swallowed whole with water (do not use other liquids); do not chew or crush. Capsules should <b>not</b> be opened, sprinkled on food, or administered via NG. Administer on an empty stomach, 1 hour before a meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for oral suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Administer on an empty stomach, 1 hour before a meal. Mix with 15 to 30 mL of water; stir well and drink immediately. Rinse cup with water and drink. Do not mix with other liquids or food, only water.</p>
<p style="text-indent:-2em;margin-left:4em;">Nasogastric/orogastric tube: Add 20 mL of water to a catheter-tipped syringe and then add contents of the prescribed packet, shake the suspension well, and administer immediately. Refill syringe with 20 mL of water, shake and flush remaining contents through tube. Suspend enteral feeding for 3 hours before and 1 hour after administering. Do not mix with other liquids or food, only water.</p></div>
<div class="block adm drugH1Div" id="F2874290"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For most indications, administer 30 to 60 minutes before a meal; best if taken before breakfast (ACG [Katz 2013]). If administering twice daily, first dose should be administered before breakfast and the second dose before dinner (ACG [Katz 2013]; Hershcovici 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Both strengths of Zegerid capsule and powder for oral suspension have identical sodium bicarbonate content, respectively. Do not substitute two 20 mg capsules/packets for one 40 mg dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Capsule:</b> Swallow whole with water (do not use other liquids); do not chew or crush. Capsules should <b>not</b> be opened, sprinkled on food, or administered via NG.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral suspension (Konvomep):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> After reconstitution, shake well before use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>NG/orogastric tube:</b> After reconstitution, shake well and withdraw 20 mL of suspension into a syringe, then administer immediately; refill syringe with 20 mL of water and flush tube to administer any remaining suspension. Suspend enteral feeding for 3 hours before and 1 hour after administering.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Powder for oral suspension (Zegerid):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Administer 1 hour before a meal. Mix with 5 to 10 mL of water; stir well and drink immediately. Rinse cup with water and drink. Do not use other liquids or sprinkle on food.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>NG/orogastric tube:</b> Mix well with 20 mL of water (do not use other liquids); shake well and administer immediately; refill syringe with 20 mL of water, shake and flush tube to administer any remaining contents. Suspend enteral feeding for 3 hours before and 1 hour after administering.</p></div>
<div class="block sts drugH1Div" id="F2874272"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules, powder for oral suspension (Zegerid and generics): Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC capsules: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension (Konvomep): Store dry powder, diluent, and reconstituted suspension at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. Once reconstituted, discard any unused portion after 30 days.</p></div>
<div class="block meg drugH1Div" id="F15664179"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Konvomep: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F213593s000lbl.pdf%23page%3D28&amp;token=hYtG7A9JrhzyvsEVUcHX3mEobuw7rXQNvPHJseAgch4UuQF9xQLUtk%2B3Ci6WbaTsHX5RMllnDNT05cvVJzU3OBxRFb4j6DaKErV191DHqxgctkDL0R19cNSEZf99g6aw&amp;TOPIC_ID=13068" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213593s000lbl.pdf#page=28</a></p>
<p style="text-indent:-2em;margin-left:4em;">Zegerid: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021849s020%2C021636s025lbl.pdf%23page%3D31&amp;token=sq8uDWTqaVWiYusLXJV5267NGcTHzztfT7SXwQ9qzuRmyGlAzuKEfqjD5tsvLUoU0lYgIvofibOU6h7mjcFCm%2BChpMf6ADcWB4xJYwd6fh6E35Ho2rrlq0FkzNebu%2BUb&amp;TOPIC_ID=13068" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021849s020,021636s025lbl.pdf#page=31</a></p></div>
<div class="block usep drugH1Div" id="F53569946"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Short-term (4 to 8 weeks) treatment of active duodenal ulcer disease or active benign gastric ulcer; treatment of symptomatic gastroesophageal reflux disease (GERD); short-term (4 to 8 weeks) treatment and maintenance healing of erosive esophagitis (Capsule, oral suspension: FDA approved in adults); reduction of risk of upper gastrointestinal bleeding in critically ill patients (Oral suspension: FDA approved in adults); relief of frequent (≥2 days/week) heartburn (OTC products: FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F7913703"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zegerid may be confused with Zestril</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Omeprazole is identified in the Beers Criteria as a potentially inappropriate medication to be avoided (as scheduled use for &gt;8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection, pneumonia, GI malignancies, and bone loss/fractures unless given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sub>2</sub> blockers) (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F2874267"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F2874266"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Acalabrutinib. This interaction is only applicable to acalabrutinib capsules. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Atazanavir.  Management: Avoid use in treatment-experienced patients. In treatment-naive patients, administer boosted atazanavir 12 hours after the PPI and the PPI dose should not exceed the equivalent of 20 mg omeprazole. Monitor for reduced atazanavir efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with inhibitors of the proton pump (PPIs and PCABs).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors and potassium-competitive acid blockers, such as short-acting antacids or histamine-2 receptor antagonists. Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: Omeprazole may increase serum concentrations of the active metabolite(s) of Cilostazol. Omeprazole may increase the serum concentration of Cilostazol.  Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving omeprazole. Monitor clinical response to cilostazol closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: Omeprazole may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with omeprazole. Monitor for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation) in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OAT1/3 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Omeprazole may decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Omeprazole may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Moderate): May decrease the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Strong): May decrease the serum concentration of Omeprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May increase the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dacomitinib.  Management: Avoid concurrent use of dacomitinib with PPIs and PCABs. Antacids may be used. Histamine H2-receptor antagonists (HR2A) may be used if dacomitinib is given at least 6 hours before or 10 hours after the H2RA.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of PPIs or PCABs if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with PPIs or PCABs should be avoided in patients treated with delavirdine. The clinical significance of short-term PPI or PCAB therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextroamphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the bioavailability of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: Omeprazole may increase the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Gefitinib.  Management: Avoid use of inhibitors of the proton pump (PPIs or PCABs) with gefitinib when possible. If required, administer gefitinib 12 hours after the PPI/PCAB or 12 hours before the next dose of the PPI/PCAB. Closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gliclazide: Omeprazole may increase the serum concentration of Gliclazide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Infigratinib. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Itraconazole. This specifically applies to the super bioavailable itraconazole products (eg, Tolsura brand). Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Itraconazole. This specifically applies to the non-super bioavailable itraconazole products (eg, Sporanox brand and its generics).  Management: Exposure to Tolsura brand itraconazole may be increased by PPIs or PCABs ; consider itraconazole dose reduction. Exposure to Sporanox brand itraconazole may be decreased. Give Sporanox brand itraconazole at least 2 hrs before or 2 hrs after PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).  Management: Administer ketoconazole with an acidic beverage, such as non-diet cola, to increase gastric acidity and improve absorption if concomitant use with proton pump inhibitors or potassium-competitive acid blockers is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Ledipasvir.  Management: PPI  or PCAB doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Use of ledipasvir with higher doses or with food, or 2 hours after a these agents, may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Levoketoconazole. Levoketoconazole may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a weak CYP2C19 inhibitor. For those stable on mavacamten who are initiating a weak CYP2C19 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Methotrexate.  Management: Consider temporarily interrupting PPI or PCAB therapy in patients receiving high-dose methotrexate. If coadministered, monitor for increased methotrexate toxicity (eg, mucositis, myalgias) and/or delayed methotrexate elimination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moclobemide: May increase the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of Moclobemide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nelfinavir.  Management: Due to potentially significant reductions in nelfinavir exposure, avoid concurrent use of nelfinavir with a PPI or PCAB when possible. If unavoidable, consider PPI or PCAB use for a short duration (less than 30 days) and closely monitor viral load.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nilotinib.  Management: Avoid this combination. Histamine H2 receptor antagonists (H2RAs) given 10 hours before or 2 hours after nilotinib, or antacids given 2 hours before or 2 hours after nilotinib are acceptable alternatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Palbociclib. Specifically, this has been reported with the use of palbociclib capsules. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Palbociclib. Specifically, this may occur with the use of palbociclib capsules, and to the greatest extent when taken without food.  Management: Carefully evaluate potential risks and benefits of coadministration of palbociclib capsules and proton pump inhibitors or potassium-competitive acid blockers due to the risk of reduced palbociclib efficacy. Palbociclib capsules should be taken with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Pexidartinib.  Management: Avoid this combination. If acid-reduction is needed, consider administering an antacid 2 hours before or after pexidartinib, or administer pexidartinib 2 hours before or 10 hours after an H2 receptor antagonist.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Posaconazole.  Management: Avoid coadministration of PPIs or PCABs and posaconazole oral suspension. Posaconazole delayed-release tablets do not appear to be sensitive to this interaction and do not required dose adjustment if coadministered with PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Risedronate. Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.  Management: Coadministration of PPIs or PCABs with delayed-release risedronate formulations is not recommended. Limit PPI/PCAB dose and duration during coadministration with risedronate as possible. Patients over age 70 are at higher risk of adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of PPIs or PCABs and secretin, and discontinue PPI or PCAB several weeks prior to secretin administration, with the duration of separation determined by the specific acid suppressant. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and PPIs or PCABs should be avoided. If coadministration cannot be avoided, selpercatinib and PPIs or PCABs should be administered simultaneously with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Omeprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Sestamibi: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Sestamibi.  Management: Consider holding/stopping proton pump inhibitor therapy for at least 3 days prior to the use technetium Tc 99m sestamibi in cardiac imaging procedures.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tetrofosmin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Tetrofosmin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: Inhibitors of the Proton Pump (PPIs and PCABs) may enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Velpatasvir.  Management: Sofosbuvir/velpatasvir should be administered with food and taken 4 hours before omeprazole 20 mg. Sofosbuvir/velpatasvir/voxilaprevir can be administered with omeprazole 20 mg. Use with other PPIs or PCABs has not been studied.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Omeprazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Omeprazole may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Omeprazole. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F2874270"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">See individual agents.</p></div>
<div class="block dic drugH1Div" id="F2874289"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Take 1 hour before a meal. Contains sodium; use with caution in patients on sodium-restricted diets. </p></div>
<div class="block pri drugH1Div" id="F2874252"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies with omeprazole. Refer to individual monographs for additional information.</p></div>
<div class="block pha drugH1Div" id="F2874273"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Suppresses gastric basal and stimulated acid secretion by inhibiting the parietal cell H+/K+ ATP pump</p></div>
<div class="block phk drugH1Div" id="F2874275"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Antisecretory: ~1 hour; Peak antisecretory effect: 2 hours; Full therapeutic effect: 1 to 4 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 72 hours; 50% of maximum effect at 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP2C19 primarily and to a lesser extent via 3A4 to hydroxy, desmethyl, and sulfone metabolites (all inactive); saturable first pass effect.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~30% to 40%; Hepatic dysfunction: ~100%; Asians: AUC increased up to 4 times compared to Caucasians.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~1 hour (range: 0.4 to 4.2 hours); Hepatic dysfunction: ~3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~0.25 to 3.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (77% as metabolites, very small amount as unchanged drug); feces.</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: 500 to 600 mL/minute; Chronic hepatic disease: 70 mL/minute.</p></div>
<div class="block phksp drugH1Div" id="F51154918"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The elimination rate of omeprazole was somewhat decreased in older patients, and bioavailability was increased. Omeprazole was 76% bioavailable when a single omeprazole 40 mg dose (buffered solution) was administered to healthy older adult subjects versus 58% in younger subjects given the same dose. Nearly 70% of the dose was recovered in urine as metabolites of omeprazole and no unchanged drug was detected. The plasma clearance of omeprazole was 250 mL/minute (about half that of younger subjects) and its plasma half-life averaged 1 hour, similar to that of younger, healthy subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961926"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Omiz plus</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aziatop quick | Ulcozol</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Pirsec</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Pirsec</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">En ao xin | Omeprazole and sodium bicarbonate</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Omefast</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Downoprazol | Omecarbex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Zegerd</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Pirsec</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Inhibitron twit</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Getzome insta</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Zegacid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Faast Plus | Izmepra plus | Loprot plus | O carb | Ombed | Omced S | Omefast | Omeprafast | Omfast | Omvic plus | Opepzole Insta | Primavera | Promiz insta | Safpep plus | Uzion</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Konvomep | Omeprazole 20mg/sodium bicarbonate 1100mg | Omeprazole and sodium bicarbonate | Omeprazole/Sodium Bicarbonate | Zegerid</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Omezyn Plus | Risek Insta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Gastrozole plus | Omiz plus</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pirsec</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al, “ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,” <i>Circulation</i>, 2010, 122(24):2619-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10690219">
<a name="10690219"></a>ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. <i>Am J Health Syst Pharm</i>. 1999;56(4):347-379. doi: 10.1093/ajhp/56.4.347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/10690219/pubmed" id="10690219" target="_blank">10690219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1764870">
<a name="1764870"></a>Andersson T, “Omeprazole Drug Interaction Studies,” <i>Clin Pharmacokinet</i>, 1991, 21(3):195-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/1764870/pubmed" id="1764870" target="_blank">1764870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11095324">
<a name="11095324"></a>Andersson T, Hassall E, Lundborg P, et al, “Pharmacokinetics of Orally Administered Omeprazole in Children. International Pediatric Omeprazole Pharmacokinetic Group,” <i>Am J Gastroenterol</i>, 2000, 95(11):3101-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/11095324/pubmed" id="11095324" target="_blank">11095324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7781266">
<a name="7781266"></a>Balian JD, Sukhova N, Harris JW, et al, “The Hydroxylation of Omeprazole Correlates With S-Mephenytoin Metabolism: A Population Study,” <i>Clin Pharmacol Ther</i>, 1995, 57(6):662-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/7781266/pubmed" id="7781266" target="_blank">7781266</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Berardi RR and Dunn-Kucharski VA, “Omeprazole: Defining Its Role in Gastroesophageal Reflux Disease,” <i>Hosp Formul</i>, 1995, 30:216-25.</div>
</li>
<li>
<div class="reference">
                  Beutler M, Hartmann K, Kuhn M, et al, “Arthralgias on Omeprazole,” <i>BMJ</i>, 1994, 309(6969):1620.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9804446">
<a name="9804446"></a>Broussard CN and Richter JE, “Treating Gastro-oesophageal Reflux Disease During Pregnancy and Lactation: What Are the Safest Therapy Options?” <i>Drug Saf</i>, 1998, 19(4):325-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/9804446/pubmed" id="9804446" target="_blank">9804446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16651285">
<a name="16651285"></a>Canani RB, Cirillo P, Roggero P, et al, "Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children," <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/16651285/pubmed" id="16651285" target="_blank">16651285</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Carvajal A and Martin Arias LH, “Gynecomastia and Sexual Disorders After the Administration of Omeprazole,” <i>Am J Gastroenterol</i>, 1995, 90(6):1028-9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10417548">
<a name="10417548"></a>Cockayne SE, Glet RJ, Gawkrodger DJ, et al, “Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,” <i>Br J Dermatol</i>, 1999, 141(1):173-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/10417548/pubmed" id="10417548" target="_blank">10417548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15818102">
<a name="15818102"></a>Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. <i>Crit Care Med</i>. 2005;33(4):760-765. doi:10.1097/01.ccm.0000157751.92249.32<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/15818102/pubmed" id="15818102" target="_blank">15818102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23034135">
<a name="23034135"></a>de Jager CP, Wever PC, Gemen EF, et al, “Proton Pump Inhibitor Therapy Predisposes to Community-Acquired <i>Streptococcus pneumoniae</i> Pneumonia,” <i>Aliment Pharmacol Ther</i>, 2012, 36(10):941-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/23034135/pubmed" id="23034135" target="_blank">23034135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29915158">
<a name="29915158"></a>Eichenwald EC; Committee on Fetus and Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants. <i>Pediatrics</i>. Published online July 2, 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/29915158/pubmed" id="29915158" target="_blank">29915158</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Epelde Gonzalo FD, Boada Montagut L, and Tomas Vecina S, “Exfoliative Dermatitis Related to Omeprazole,” <i>Ann Pharmacother</i>, 1995, 29(1):82-3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fass R. Approach to refractory gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2020.</div>
</li>
<li>
<div class="reference">
                  Feldman M. NSAIDs (including aspirin): secondary prevention of gastroduodenal toxicity. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10201459">
<a name="10201459"></a>Festen HP, Schenk E, Tan G, Snel P, Nelis F; The Dutch Reflux Study Group. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. <i>Am J Gastroenterol</i>. 1999;94(4):931-936. doi:10.1111/j.1572-0241.1999.989_l.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/10201459/pubmed" id="10201459" target="_blank">10201459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25192903">
<a name="25192903"></a>Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. <i>Fam Pract</i>. 2014;31(6):625-630. doi:10.1093/fampra/cmu050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/25192903/pubmed" id="25192903" target="_blank">25192903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21126704">
<a name="21126704"></a>Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. <i>Best Pract Res Clin Gastroenterol</i>. 2010;24(6):923-936. doi:10.1016/j.bpg.2010.10.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/21126704/pubmed" id="21126704" target="_blank">21126704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17956960">
<a name="17956960"></a>Johnson CE, Cober MP, and Ludwig JL, "Stability of Partial Doses of Omeprazole-Sodium Bicarbonate Oral Suspension," <i>Ann Pharmacother</i>, 2007, 41(12):1954-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/17956960/pubmed" id="17956960" target="_blank">17956960</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kahrilas PJ. Medical management of gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2020.</div>
</li>
<li>
<div class="reference">
                  Kane DL, “Administration of Omeprazole (Prilosec®) in the Atypical Patient,” <i>Int J Pharm Compounding</i>, 1997, 1(1):13.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23419381">
<a name="23419381"></a>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2013;108(3):308-329. doi:10.1038/ajg.2012.444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/23419381/pubmed" id="23419381" target="_blank">23419381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767318">
<a name="29767318"></a>Kim J, Blackett JW, Jodorkovsky D. Strategies for effective discontinuation of proton pump inhibitors. <i>Curr Gastroenterol Rep</i>. 2018;20(6):27. doi:10.1007/s11894-018-0632-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/29767318/pubmed" id="29767318" target="_blank">29767318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Azurity.1">
<a name="Azurity.1"></a>Konvomep (omeprazole/sodium bicarbonate) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference">
                  Kraus A and Flores-Suarez LF, “Acute Gout Associated With Omeprazole,” <i>Lancet</i>, 1995, 345(8947):461-2.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1624174">
<a name="1624174"></a>Larner AJ and Lendrum R, “Oesophageal Candidiasis After Omeprazole Therapy,” <i>Gut</i>, 1992, 33(6):860-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/1624174/pubmed" id="1624174" target="_blank">1624174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10922420">
<a name="10922420"></a>Lau JY, Sung JJ, Lee KK, et al, “Effect of Intravenous Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers,” <i>N Engl J Med</i>, 2000, 343(5):310-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/10922420/pubmed" id="10922420" target="_blank">10922420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064601">
<a name="22064601"></a>Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” <i>Circulation</i>, 2011, 124(23):e574-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/22064601/pubmed" id="22064601" target="_blank">22064601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9201091">
<a name="9201091"></a>Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. <i>Dig Dis Sci.</i> 1997;42(6):1255-1259. doi: 10.1023/a:1018810325370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/9201091/pubmed" id="9201091" target="_blank">9201091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA, and Section on Gastroenterology, Hepatology, and Nutrition, "Gastroesophageal Reflux: Management Guidance for the Pediatrician," <i>Pediatrics</i>, 2013, 131(5):e1684-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lindquist M and Edwards IR, “Endocrine Adverse Effects of Omeprazole,” <i>Br Med J</i>, 1992, 305(6851):451-2.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31175146">
<a name="31175146"></a>Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early acid suppression therapy exposure and fracture in young children. <i>Pediatrics</i>. 2019;144(1):e20182625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/31175146/pubmed" id="31175146" target="_blank">31175146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10772433">
<a name="10772433"></a>Natsch S, Vinks MH, Voogt AK, et al, “Anaphylactic Reactions to Proton-Pump Inhibitors,” <i>Ann Pharmacother</i>, 2000, 34(4):474-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/10772433/pubmed" id="10772433" target="_blank">10772433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25112692">
<a name="25112692"></a>Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. <i>J Pediatr</i>. 2014;165(5):979-984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/25112692/pubmed" id="25112692" target="_blank">25112692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7789474">
<a name="7789474"></a>Ottervanger JP, Stricker BH, Kappelle JW, et al, “Omeprazole-Associated Agranulocytosis,” <i>Eur J Haematol</i>, 1995, 54(4):279-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/7789474/pubmed" id="7789474" target="_blank">7789474</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Prilosec (omeprazole/omeprazole magnesium) [prescribing information]. Wilmington, DE: AstraZeneca LP; December 2014.</div>
</li>
<li>
<div class="reference">
                  Province of British Columbia Ministry of Health. Proton pump inhibitors in primary care. <i>B.C. Provincial Academic Detailing Service</i>. Updated January 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12095478">
<a name="12095478"></a>Ramakrishnan A, Katz PO. Pharmacologic management of gastroesophageal reflux disease. <i>Curr Treat Options Gastroenterol</i>. 2002;5(4):301-310. doi:10.1007/s11938-002-0053-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/12095478/pubmed" id="12095478" target="_blank">12095478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1987878">
<a name="1987878"></a>Soll AH, Weinstein WM, Kurata J, et al, “Nonsteroidal Anti-inflammatory Drugs and Peptic Ulcer Disease,” <i>Ann Intern Med</i>, 1991, 114(4):307-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/1987878/pubmed" id="1987878" target="_blank">1987878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11329761">
<a name="11329761"></a>Song JC, Quercia RA, Fan C, et al, “Pharmacokinetic Comparison of Omeprazole Capsules and a Simplified Omeprazole Suspension,” <i>Am J Health Syst Pharm</i>, 2001, 58(8):689-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/11329761/pubmed" id="11329761" target="_blank">11329761</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Spechler SJ. Barrett's esophagus: surveillance and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047577">
<a name="20047577"></a>Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. <i>Aliment Pharmacol Ther</i>. 2010;31(7):754-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/20047577/pubmed" id="20047577" target="_blank">20047577</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vakil NB. Peptic ulcer disease: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2020b.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/Vakil.2020.1/pubmed" id="Vakil.2020.1" target="_blank">Vakil.2020.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.2020.1">
<a name="Vakil.2020.1"></a>Vakil NB. Peptic ulcer disease: treatment and secondary prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 1, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30094626">
<a name="30094626"></a>Waghray A, Waghray N, Perzynski AT, Votruba M, Wolfe MM. Optimal omeprazole dosing and symptom control: a randomized controlled trial (OSCAR Trial). <i>Dig Dis Sci</i>. 2019;64(1):158-166. doi:10.1007/s10620-018-5235-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/30094626/pubmed" id="30094626" target="_blank">30094626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19821323">
<a name="19821323"></a>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. <i>Cochrane Database Syst Rev</i>. 2009;(4):CD004275. doi:10.1002/14651858.CD004275.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/19821323/pubmed" id="19821323" target="_blank">19821323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32176276">
<a name="32176276"></a>Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association between proton pump inhibitor use and risk of fracture in children. <i>JAMA Pediatr</i>. Published online March 16, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/32176276/pubmed" id="32176276" target="_blank">32176276</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Weinhouse GL. Stress ulcers in the intensive care unit: diagnosis, management, and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2022.</div>
</li>
<li>
<div class="reference">
                  Wolfe MM. Proton pump inhibitors: overview of use and adverse effects in the treatment of acid related disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10868896">
<a name="10868896"></a>Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. <i>Gastroenterology</i>. 2000;118(2)(suppl 1):S9-S31. doi:10.1016/s0016-5085(00)70004-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/10868896/pubmed" id="10868896" target="_blank">10868896</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Woods DJ and McClintock AD, “Omeprazole Administration,” <i>Ann Pharmacother</i>, 1993, 27(5):651.</div>
</li>
<li>
<div class="reference">
                  Zegerid (omeprazole/sodium bicarbonate) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ZegeridOTC.1">
<a name="ZegeridOTC.1"></a>Zegerid OTC (omeprazole/sodium bicarbonate) [prescribing information]. New York, NY: Riley Consumer Care; received December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11394727">
<a name="11394727"></a>Zimmermann AE, Walters JK, Katona BG, et al, “A Review of Omeprazole Use in the Treatment of Acid-Related Disorders in Children,” <i>Clin Ther</i>, 2001, 23(5):660-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-and-sodium-bicarbonate-pediatric-drug-information/abstract-text/11394727/pubmed" id="11394727" target="_blank">11394727</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13068 Version 299.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
